BAVA:CPH
Bavarian Nordic
210,40Â DKK
arrow_downward
-0,66%(-1,40) 1G
8 set, 14:15:16 GMT+2 · DKK
search
Tutti i simboli
1G
5G
1M
6M
YTD
1A
5A
MAX
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per BAVA in corso…
Apertura
210,40Â DKK
Massimo
212,00Â DKK
Minimo
209,00Â DKK
Cap. mercato
17,08Â Mld
Vol. medio
211,21K
Volume
52,53K
Max 52 sett.
243,70Â DKK
Min 52 sett.
171,30Â DKK
Azioni in circolazione
79,27Â Mln
N. di dipendenti
2K
Apertura
210,40Â DKK
Massimo
212,00Â DKK
Minimo
209,00Â DKK
Cap. mercato
17,08Â Mld
Vol. medio
211,21K
Volume
52,53K
Max 52 sett.
243,70Â DKK
Min 52 sett.
171,30Â DKK
Azioni in circolazione
79,27Â Mln
N. di dipendenti
2K
Articoli giornalistici
Da fonti web e partner giornalistici
Profilo
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination. In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
Informazioni su Bavarian Nordic